Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer

• Published in: Scientific reports 2022-03, Vol.12 (1), p.5055-5055, Article 5055
• Main Authors: Yamazaki, Hideya, Masui, Koji, Suzuki, Gen, Aibe, Norihiro, Shimizu, Daisuke, Kimoto, Takuya, Yamada, Kei, Ueno, Akihisa, Matsugasumi, Toru, Yamada, Yasuhiro, Shiraishi, Takumi, Fujihara, Atsuko, Yoshida, Ken, Nakamura, Satoaki
• Format: Article
• Language: English
• Subjects: 692/4025; 692/4028; Brachytherapy; Brachytherapy - adverse effects; Humanities and Social Sciences; Humans; Male; multidisciplinary; Prostate cancer; Prostatic Neoplasms - etiology; Prostatic Neoplasms - radiotherapy; Radiation therapy; Radiotherapy Dosage; Retrospective Studies; Science; Science (multidisciplinary); Toxicity; Urogenital System
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-09120-0

To compare gastrointestinal (GI) and genitourinary (GU) toxicities in patients with localized prostate cancer treated with ultrahypofractionated radiotherapy (UHF) or brachytherapy [BT; low dose rate, LDR or high dose rate (HDR) with or without external beam radiotherapy (EBRT)]. We compared 253 UHF and 1664 BT ± EBRT groups. The main outcomes were the incidence and severity of acute and late GU and GI toxicities. The secondary endpoint was biochemical control rate. Cumulative late actuarial GU toxicity did not differ for grade ≥ 2 (8.6% at 5-years in UHF and 13.3% in BT ± EBRT, hazard ratio [HR], 0.7066; 95% CI, 0.4093–1.22, p = 0.2127). Actuarial grade ≥ 2 late GI toxicity was higher in UHF (5.8% at 5-years, HR: 3.619; 95% CI, 1.774–7.383, p